Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at statnews.com →

More in Health & Medicine

More from Sunday 15 November →